61Cu-NODAGA-LM3

## Drug Overview 61Cu-NODAGA-LM3 is a novel positron emission tomography (PET) imaging agent being developed for the detection of neuroendocrine tumors (NETs). It combines copper-61 (61Cu) as the radioisotope with NODAGA-LM3, a somatostatin receptor antagonist that targets somatostatin receptor subtype 2 (SST2), which is characteristically overexpressed in neuroendocrine tumors[1][2]. This radiopharmaceutical is currently being evaluated in clinical trials, specifically in the COPPER PET in NET study, which aims to compare its safety and sensitivity to the current standard-of-care PET agent, 68Ga-DOTATOC[2][4]. The study is a monocentric, open-label, randomized-controlled, reader-blind clinical trial being conducted at the University Hospital Basel in Switzerland[2][4]. ## Development and Properties 61Cu-NODAGA-LM3 was developed through a collaboration between University Hospital Basel and Nuclidium AG[1][6]. Dr. Melpomeni Fani at University Hospital Basel is leading the research, which received funding from the Neuroendocrine Tumor Research Foundation (NETRF) in 2022[1][5]. The agent is expected to offer several advantages over current standard-of-care PET agents used for NET imaging: - Enhanced tumor uptake and retention compared to established radiolabeled somatostatin receptor agonists[2] - Improved image contrast for better tumor detection[2] - Longer half-life than gallium-68 based agents, allowing for delayed imaging and potential shipment to smaller centers[2] - Reduced physiological uptake in organs like the liver, which can improve detection of liver metastases[2] - Potentially lower cost and wider availability[1] ## Clinical Development The clinical development of 61Cu-NODAGA-LM3 is progressing through the following stages: 1. Establishment of 61Cu production at two European sites (Switzerland and Germany) using Nuclidium AG's proprietary technology[1] 2. Development of 61Cu-NODAGA-LM3 production for human use[1] 3. Phase 0/I clinical study in Switzerland to assess safety, biodistribution, pharmacokinetics, and dosimetry in NET patients[1][2][4] 4. Head-to-head comparison with 68Ga-DOTATOC PET/CT in the same patients[1][2][4] The current clinical trial (COPPER PET in NET, NCT06455358) is actively recruiting patients with well-differentiated bronchopulmonary and gastroenteropancreatic neuroendocrine tumors[2][4]. Eligible participants must be 18 years or older with a confirmed diagnosis of well-differentiated NETs[4]. Upon completion of the phase 0/I study, a phase II study is already planned to be conducted in Switzerland, Germany, and the United States[1]. Nuclidium AG has expressed interest in commercializing 61Cu-NODAGA-LM3 in the United States and other countries following successful clinical evaluation[1]. ## Chemical and Pharmacological Properties 61Cu-NODAGA-LM3 is described as relatively hydrophilic and carries no charge[9]. The NODAGA chelator is used to conjugate the copper-61 radioisotope to the LM3 peptide, which is a somatostatin receptor antagonist[6][9]. The radiopharmaceutical targets somatostatin receptor subtype 2 (SST2), which is overexpressed in many neuroendocrine tumors[2]. As an antagonist, it may offer advantages over agonist-based imaging agents in terms of tumor uptake and image contrast[2]. This innovative approach to NET imaging represents a promising advancement in the field of nuclear medicine and could potentially improve the diagnosis and management of patients with neuroendocrine tumors.